This post is from a suggested group
Biopharmaceutical Innovation in India: Core Therapeutic Areas, Advancement in Biosimilars, and the Development of Advanc
India is rapidly evolving into a hub for the development and manufacturing of complex biological medicines, often referred to as biologics. These therapies are proteins derived from living organisms, differing significantly from traditional small-molecule drugs.
Therapeutic Focus: Key areas of innovation include Oncology (cancer treatment), Immunology (for autoimmune disorders like arthritis), and Vaccines (such as tetravalent influenza vaccines). There is also rising interest in cutting-edge therapies like Cell and Gene Therapy (CGT).
Biosimilars and Biobetters: A major strength lies in the capability to produce biosimilars—highly similar versions of approved reference biologics—which increases access to expensive treatments for conditions like inflammatory arthritis. The focus is now shifting to developing 'biobetters' and novel biologics with enhanced performance.
Infrastructure Investment: Dedicated bioprocess design centers and R&D facilities are being established to provide expertise in advanced techniques like cell culture and purification, aiming to bridge the national skill gap and accelerate the scale-up of therapeutic development.